Astec Lifesciences Ltd - Stock Valuation and Financial Performance

BSE: 533138 | NSE: ASTEC | Pesticides & Agrochemicals | Small Cap

Astec Lifesciences Share Price

1,284.95 -11.10 -0.86%
as on 12-Apr'24 16:59

DeciZen - make an informed investing decision on Astec Lifesciences

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Astec Lifesciences stock performance -

mw4me loader
P/E Ratio (CD):
0.00
Market Cap:
2,519.7 Cr.
52-wk low:
826.2
52-wk high:
1,540

Is Astec Lifesciences Ltd an attractive stock to invest in?

1. Is Astec Lifesciences Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Astec Lifesciences Ltd is a below average quality company.

2. Is Astec Lifesciences Ltd undervalued or overvalued?

The key valuation ratios of Astec Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Astec Lifesciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Astec Lifesciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Astec Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Astec Lifesciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 9.2%17.2%5.7%10.8%9.1%12.8%14.5%15.7%15.3%4.8%-
Value Creation
Index
-0.40.2-0.6-0.2-0.4-0.10.00.10.1-0.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 207267247299368431523555677628431
Sales YoY Gr.-29%-7.5%20.9%23.1%17.2%21.3%6.2%21.9%-7.2%-
Adj EPS 5.814.12.39.79.217.722.43242.510.2-26
YoY Gr.-144.5%-83.8%324%-5.2%91.9%26.5%43.3%32.9%-76.1%-
BVPS (₹) 61.369.660.370.486.4103.2125.7157.6202.2213.7189
Adj Net
Profit
10.727.54.518.91834.643.762.783.419.9-51
Cash Flow from Ops. 14.67.5-12.519.264.715.3168-8.223.674.7-
Debt/CF from Ops. 5.712.5-10.16.61.911.50.6-22.911.84.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 13.1%11.3%6.3%-7.2%
Adj EPS 6.5%2%-23.1%-76.1%
BVPS14.9%19.9%19.4%5.7%
Share Price 43.6% 20.3% 7.3% -5.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
9.822.13.514.811.718.619.522.623.64.9-12.9
Op. Profit
Mgn %
18.220.713.92118.717.816.320.122.812.2-3.1
Net Profit
Mgn %
5.210.31.86.44.988.411.312.33.2-11.8
Debt to
Equity
0.70.71.10.90.70.90.40.60.70.8-
Working Cap
Days
219223304248233223217229244316159
Cash Conv.
Cycle
113841059192956053102155-10

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.81

Return on Equity is Poor

Sales growth has been subdued in last 3 years 6.32%

Sales growth is not so good in last 4 quarters at -44.25%

Latest Financials - Astec Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) -26 -26
TTM Sales (₹ Cr.) 431 431
BVPS (₹.) 188.7 189
Reserves (₹ Cr.) 350 351
P/BV 6.81 6.80
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 826.15 / 1540.00
All Time Low / High (₹) 14.45 / 2285.65
Market Cap (₹ Cr.) 2,520
Equity (₹ Cr.) 19.6
Face Value (₹) 10
Industry PE 36.1

Management X-Ray of Astec Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Astec Lifesciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales207267247299368431523555677628
Operating Expenses 172213215236299354437443522552
Manufacturing Costs1571922253239385264
Material Costs133179161180235279339342387401
Employee Cost 11121620222530385052
Other Costs 12152014171730253335
Operating Profit 3554326269768511115476
Operating Profit Margin (%) 17.1%20.3%12.8%20.9%18.7%17.7%16.3%20.1%22.8%12.1%
Other Income 01738111281013
Interest 91313121112135921
Depreciation 15131014151923263434
Exceptional Items -1-17-3-11400000
Profit Before Tax 111312295656618912135
Tax 2-271021201424319
Profit After Tax 915519353648659026
PAT Margin (%) 4.2%5.5%2.1%6.4%9.5%8.3%9.1%11.7%13.3%4.1%
Adjusted EPS (₹)4.77.62.69.817.918.324.333.245.913.0
Dividend Payout Ratio (%)21%16%0%15%8%8%6%5%3%12%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 113135117137169202246309396419
Share Capital 19191920202020202020
Reserves 9511698118149182226289377399
Minority Interest0000000000
Debt759111712612417699187239296
Long Term Debt18138000040011
Short Term Debt577710912612417699147239285
Trade Payables4688685710063202128190177
Others Liabilities 504825132020245310087
Total Liabilities 284362328334413461572678925979

Fixed Assets

Gross Block188201105124150221271316477488
Accumulated Depreciation55681022355477103137170
Net Fixed Assets13213395103115167194213340318
CWIP 61220842192411623127
Investments 0000000000
Inventories777271667893121106187295
Trade Receivables5110481111123122161187274155
Cash Equivalents 41264111222
Others Assets142955435359705410082
Total Assets 284362328334413461572678925979

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 157-13196515168-82475
PBT 111912295656618912135
Adjustment 22231935183037294451
Changes in Working Capital -17-32-39-386-5588-103-112-6
Tax Paid -2-3-5-7-15-16-18-23-29-5
Cash Flow From Investing Activity -19-19-16-18-49-52-74-73-104-113
Capex -19-20-26-20-50-53-45-103-104-116
Net Investments 0082000000
Others 012010-292904
Cash Flow From Financing Activity 31231-1-1837-95818038
Net Proceeds from Shares 0000000100
Net Proceeds from Borrowing -3-50000040016
Interest Paid -8-11-13-12-11-12-13-5-9-20
Dividend Paid -2-2-30-3-3-3-3-3-3
Others 16304611-552-79489245
Net Cash Flow -1021-300000
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)7.9111.884.0115.0722.919.3121.2423.4625.56.28
ROCE (%)10.8811.9610.6516.0823.7520.3120.4422.2922.217.75
Asset Turnover Ratio0.810.880.720.950.990.991.020.890.850.66
PAT to CFO Conversion(x)1.670.47-2.611.860.423.5-0.120.272.88
Working Capital Days
Receivable Days9510013611111510398114124124
Inventory Days10696106807172747479139
Payable Days126136177127122107143176150167

Astec Lifesciences Ltd Stock News

Astec Lifesciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Astec Lifesciences on 12-Apr-2024 16:59 is ₹1,285.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2024 16:59 the market cap of Astec Lifesciences stood at ₹2,519.7.
The latest P/E ratio of Astec Lifesciences as of 12-Apr-2024 16:59 is 0.00.
The latest P/B ratio of Astec Lifesciences as of 12-Apr-2024 16:59 is 6.81.
The 52-week high of Astec Lifesciences is ₹1,540 and the 52-week low is ₹826.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Astec Lifesciences is ₹431.4 ( Cr.) .

About Astec Lifesciences Ltd

Astec is proud of its rich experience of over two decades in the chemical industry. The company employs highly qualified and trained personnel to monitor and maintain its manufacturing activities as well as process development work. Astec prides itself in being responsive, reliable and quick to implement projects. A strong R&D focus has enabled the company to introduce a number of unique products. As the operations are highly integrated both vertically and horizontally, Astec has a very efficient, low cost structure in the market place.

Strong emphasis on quality, backed by a highly competent technical team, has enabled Astec to establish a successful track record in nurturing stable and long term relationships with highly reputed companies in USA, Japan and Europe. Above all, utmost respect for confidentiality, reliability, integrity and commitment in all its business relationships make Astec an ideal outsourcing partner. Astec Chemicals operates an ISO 9001:2000 certified Quality Assurance system.

The company has technologically sophisticated facilities for process development work and has demonstrated its ability to synthesize complex molecules rapidly. All its laboratories are equipped to carry out reactions from gm-scale to kilo-scale {up to 20 litres}.

Scale up to multikilo level is undertaken at its versatile 50-500 lts capacity pilot plant. Setting up a feasibility study through to laboratory development, pilot scale-up and full scale production are governed by the highest safety, quality and environmental standards.

Astec has multipurpose production facilities at two locations.

• Dombivli (50 km from Mumbai) • Mahad - two plants ( 180 kms from Mumbai)

They are multi-purpose plants based on 3,000-20,000 litres glasslined and stainless steel reactors. Typical reactors sizes are 10,000 lts.

• The pilot plant has glass and SS vessels of 50 litres to 500 litres capacity. • Reactions can be carried out from minus 20o C to 250o C. Distillation up to 300C • Vacuum down to 1mm Hg. • Distillation systems can handle high melting solids. • High efficiency fractionating columns up to 40 theoretical plates are available. • Facilities are designed to handle a number of corrosive and hazardous raw materials.

Products:

• Tebuconazole • Hexaconazole • Propiconazole • Metalaxyl • 1,2 Pentanediol • Dicap • 4-Fluoro phenacyl chloride.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.